Please login to the form below
Microbiome
This page shows the latest Microbiome news and features for those working in and with pharma, biotech and healthcare.
Seres’ microbiome-based therapy hits the mark in phase 3
Drug reduced C.difficile infection recurrence. Seres Therapeutics has reported positive topline data from a phase 3 trail of its microbiome therapy SER-109 for recurrent C.difficile infections. ... SER-109 is an oral, biologically-derived microbiome
Latest news
-
Bayer bulks up in women’s health again with non-hormonal contraceptive deal
The Evotec and Daré deals sandwiched two other agreements signed in the last few days, including a partnership with Azitra to develop skin microbiome-based treatments for eczema, and another with
-
Finch Therapeutics bags $53m for microbiome therapies
Finch’s pipeline includes CP101, an oral capsule that contains a diverse community of microbiota to restore a balanced microbiome. ... Prior studies have suggested the link between the two is a disrupted microbiome.
-
AZ signs $20m deal with Seres for microbiome project
of Seres’ microbiome candidates – SER-401 – tested in combination with AZ’s cancer therapies including its PD-L1 checkpoint inhibitor Imfinzi (durvalumab). ... One of the targets of the AZ-backed project will be to see if the microbiome can serve
-
Finch’s microbiota drug for C. diff gets FDA breakthrough status
diff – along with other beneficial bacteria in the gut – they can be used to restore the balance of the bacterial colonies or ‘microbiome’ that naturally populate our bodies. ... Takeda bought into the programme in 2017, and is also partnering
-
Ex-Pharmacyclics CEO invests $25m in Summit
damaging to the normal microbiome of the gastrointestinal tract. ... Preserving the microbiome makes it less likely that the pathogen can re-establish itself once treatment finishes, it suggests.
More from news
Approximately 7 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
Takeda’s strategy is to develop GI products that address the highest unmet needs, which includes projects across three novel platforms – gene therapy, microbiome and cell therapy.
-
A snapshot of Microbiotica
How is Microbiotica advancing life sciences with its technology? Microbiotica is a leading expert in the microbiome and is using its technology to identify the good and bad microbiomes in patients. ... There is also a $534m collaboration with Roche’s
-
Pharma’s coral reef
If you need another example, look in the mirror and consider that a large part of the creature facing you is made of other organisms, such as those in your microbiome.
-
Deal Watch November 2016
immuno-oncology collaboration based on Enterome's microbiome technology.
-
Building the Future
The human microbiome is an example of this but a coral reef is a better one.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Former Genzyme group vice president joins Vedanta Biosciences
His experience and leadership in pioneering new drug modalities will be invaluable as we advance our pipeline of microbiome-modulating therapies.”. ... Dr Roberts said: “Microbiome modulation is among the most exciting and rapidly evolving fields in
-
Vedanta Biosciences appoints two new heads
Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.
-
Ritter Pharmaceuticals appoints new CMO
Ritter is currently developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. ... microbiome. “I believe my experience in product development coupled with my research capabilities will be a great
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Mastering the precision medicine opportunity
This data will come from a patient’s genetics, electronic health records, microbiome, diet, lifestyle, and will be the driving force behind improved outcomes.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
